Adrian Banning

Adrian Banning is a Professor of Interventional Cardiology at the University of Oxford's Radcliffe Department of Medicine. His research focuses on mechanisms of myocardial injury during percutaneous coronary intervention (PCI), reperfusion in ST-elevation myocardial infarction (STEMI), and the clinical application of drug-eluting stents (DES) and intravascular ultrasound (IVUS). He has led landmark clinical trials such as the SYNTAX trial (comparing DES with coronary artery bypass grafting) and the HORIZONS trial (primary PCI in acute myocardial infarction). His work has influenced international guidelines for revascularization strategies and biochemical definitions of cardiac injury.

Key contributions include advancing day-case PCI protocols, paramedic-delivered clopidogrel for AMI patients, and Oxford's region-wide Primary PCI service. He co-authored national guidelines for valvular heart disease management and leads projects on transcatheter aortic valve implantation (TAVI). Banning has an h-index of 43 and over 200 peer-reviewed publications, with recent work exploring cerebral embolic protection in TAVI and photon-counting CT angiography for coronary assessment.

His clinical leadership roles include Principal Investigator for multiple international trials (e.g., TAXUS, SYNTAX) and recruitment success in pivotal studies like Excel (left main coronary disease trial). He has trained numerous interventional cardiologists and maintains active collaborations with industry and NHS services to improve cardiac care delivery and outcomes.